0 Ratings

ID

22718

Description

Study part: PGx- Pharmacogenetic Research Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Keywords

Hypereosinophilic Syndrome

Clinical Trial

Pharmacogenetics

6/11/17 6/11/17 -

Copyright Holder

GlaxoSmithKline

Uploaded on

June 11, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments

Itemgroup comments for :

Item comments for :

No comments

In order to download data models you must be logged in. Please log in or register for free.

PGx- Pharmacogenetic Research Screening Visit Mepolizumab HES NCT00086658

model
Details